OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in HIV and AIDS is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	39
Editorial introductions	39
Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research	35
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	30
Future options for long-acting HIV treatment and prevention	26
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	23
The sounds of silencing: dynamic epigenetic control of HIV latency	23
Editorial introductions	22
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	21
Harnessing natural killer cells to target HIV-1 persistence	20
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure	20
Editorial introduction	19
Pulse check: modern strategies for cardiovascular risk in women with detection and prevention in women with HIV	17
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	17
Challenges towards an AIDS-free generation in Africa and Asia	17
The double burden: navigating HIV co-infections with HCV, HBV, and Mtb	16
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	16
Loneliness and social isolation in people with HIV	15
Editorial introduction	15
Persistent elite controllers as the key model to identify permanent HIV remission	14
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	14
Editorial introduction	14
New latency-promoting agents for a block-and-lock functional cure strategy	14
Estrogen depletion and immune activation and inflammation in women with HIV	13
Balancing polypharmacy and comorbidity management: cardiovascular health	13

Editorial introduction	13
Public health surveillance and outbreak preparedness for mpox	13
Impact of coronavirus disease 2019 on co-morbidities in HIV	13
Defining multimorbidity in people with HIV – what matters most?	13
The origins of new SARS-COV-2 variants in immunocompromised individuals	13
Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	13
Stigma as a facilitator of the 2022 mpox outbreak	13
Viral and immune predictors of HIV posttreatment control	12
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	12
Aging of adult lifetime survivors with perinatal HIV	12
Integrating substance use services into HIV care: an underused implementation science opportunity	12
Learned young: HIV-1 germline-targeting vaccination in infants	11
New vector and vaccine platforms: mRNA, DNA, viral vectors	11
The multifaceted nature of HIV tissue reservoirs	11
Role of follicular homing natural killer cells in HIV infection	10
Mpox and the impact on people with HIV	10
Gender and sex considerations in HIV and bone health	9
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	9
Obesity among women with HIV	9
Broadly neutralizing antibodies for HIV treatment and cure approaches	9
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	8
Host factors predisposing to kidney disease in people with HIV	8
The severity of COVID-19 across the spectrum of HIV	8
Causes and outcomes of hepatic fibrosis in persons living with HIV	8
Metabolic dysfunction-associated steatotic liver disease in people with HIV	8
Maintain the gains: methods to evaluate the sustainability and scalability of HIV-related prevention, care, and treatment programs	8
Editorial introductions	8
Editorial introduction	8
Single-cell sequencing technologies: a multiomics toolbox for investigating HIV-1 persistence	8
Use of implementation theories, models, and frameworks in PrEP implementation research from 2022–2025: innovation and participation	8
Editorial introductions	8
Roadmap for spatial transcriptomics of HIV in tissues	8
Mpox in 2026: what we knew, what we have learned, and what we still have to learn	7
Innate immune mechanisms in HIV elite controllers	7
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
Innovative models of care supporting people aging with HIV	7
Contemporary issues in gynecologic and reproductive health for women with HIV	7
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	7
Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance	7
Persistent HIV-1 transcription during ART: time to reassess its significance?	7
Editorial introductions	7
Editorial introductions	7
Strategies to target the central nervous system HIV reservoir	7
Natural killer cells in pediatric HIV cure strategies: from viral control to immunotherapeutics	6
The pathogenesis of obesity in people living with HIV	6
Evaluating immunotherapy as a pathway toward HIV cure	6
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	6
BACH2 effector-to-memory switch promotes HIV persistence and CAR-T efficacy	6
HIV-1 subtypes and latent reservoirs	6
Hepatitis C elimination in people with HIV: progress, gaps, and future directions	6

Towards an HIV cure: one cell at a time	6
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	6
The role of analytical treatment interruptions in shaping HIV-specific immunity and HIV cure	6
Whole person HIV services: a social science approach	6
What can spontaneous controllers, posttreatment controllers and postintervention controllers teach us about an HIV cure?	6
Care of people aging with HIV in resource limited settings	5
Editorial introductions	5
Single cell analyses of the HIV reservoir in the CNS and CSF: recent insights and implications	5
Humanized mice for studying HIV latency and potentially its eradication	5
The power of ten in HIV remission: insights from hematopoietic stem cell transplantation	5
Editorial introductions	5
Editorial introductions	5
Promoting patient-centered care within HIV care settings in sub-Saharan Africa	5
Cognitive impairment in persons with HIV: changing aetiologies and management strategies	5
It's all in the gut: the central role of the gut and microbiome in preventing disease progression in simian immunodeficiency viruses infected African nonhuman primates	5
Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission	5
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	5
γc-cytokines in HIV Cure Research	5
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?	5
Editorial: HIV and cardiovascular disease: recognizing and reducing disparities	5
The state of the art of adaptation strategies for HIV-related interventions	5
Rethinking aging biomarkers in HIV: from measures to meaning	5
Human papillomavirus infection among adolescents living with HIV: a focus on prevention	5
Editorial introduction	4
Delivery platforms for broadly neutralizing antibodies	4
How nonhuman primate infant and mother-infant models can inform pediatric HIV-1 cure research	4
Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV	4
Management of pain and other palliative needs in older people with HIV	4
Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control	4
An evidence-based call for tailored interventions to support women with HIV who use substances	4
The female microbiome in HIV prevention, pathogenesis, and treatment	4
Zika virus: an overview update	4
Monocytes across life span in HIV infection: lights and shadows	4
A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment	4
HIV T-cell immunogen design and delivery	4
Pediatric immunotherapy and HIV control	4
Targeting HIV myeloid and central nervous system reservoirs for HIV cure	4
Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions	4
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	4
Using single cell technologies to understand HIV latency models	4
The vaginal microbiome and HIV transmission dynamics	4
Geriatric syndromes in women living with HIV	3
Elite controllers microbiome: unraveling the mystery of association and causation	3
HIV cure: an acceptability scientific agenda	3
Stepping stones to cure in children with HIV	3
HIV and obesity: updates in management strategies	3
Understanding residual risk of cardiovascular disease in people with HIV	3
Post-intervention control in HIV immunotherapy trials	3
Long-acting preexposure prophylaxis: early data on roll-out in the United States	3
Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings	3
Editorial introductions	3
Barriers and facilitators related to COVID-19 vaccine acceptance and uptake among people living with HIV	3
Mycobacterium tuberculosis in HIV co-infection: a growing concern in Europe?	3
Utilizing immunotherapy towards achieving a functional cure for HIV-1	3
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection	3
Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development	3
Modeling the fallout: projecting the global impact of donor funding cuts on HIV prevention, treatment, and care	3
Public health services and intersectional stigma: a social sciences perspective with implications for HIV service design and delivery	3
Humoral immunity in HIV-1 post-treatment controllers	3
Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention	3
Pulmonary comorbidities in people with HIV− the microbiome connection	3
Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research	3